Credible, reliable, high quality, and relevant evidence-based analysis.
Why NHTA is your partner for Health Economics
Decision makers are becoming increasingly cost-aware, and the cost-effectiveness and budget impact of your product are primarily the determining factors when deciding on reimbursement or standard treatment. In order for authorities to accept a health economic model, it needs to meet the country specific requirements and reflect local clinical practice. Ensuring that your health economic model is user friendly, transparent, and adaptable will increase the assessor’s confidence in the model, which in turn results in a more efficient process, shorter processing time, easier decision making and earlier market access
NHTA has extensive experience in developing, assessing and adapting HE models to support your economic value proposition. We work with you to understand your needs before delivering bespoke health economic models that can deliver metrics needed to demonstrate the health economic value of your product.
Early health technology assessment is increasingly important and a key component of HEOR planning, informing research and development about the design and key value drivers, and ensuring that resources are deployed in areas where information gaps are most problematic and the expected return on investment in evidence generation activities is greatest.
Our team of skilled health economic modellers and statisticians have excessive knowledge and experience with developing cost-effectiveness models and analyses. At NHTA we excel in delivering transparent and user-friendly models that fit your requirements and value communication strategy.
Budget-Impact & Payers Engagement Tools
Budget impact plays an important role in payer decision making. We have built and adapted various budget impact models and payer engagement tools. NHTA is your partner for budget impact models and payer engagement tools.
Burden of Illness
Burden of illness assesses the epidemiological, health-related quality-of-life (HRQoL), and economic impact of disease. Such assessments support value propositions, pricing strategies, and reimbursement and utilization decisions, and they also highlight evidence gaps.